ARTICLE | Company News
BioTime, Summit Pharmaceuticals deal
January 3, 2005 8:00 AM UTC
The companies partnered to develop BTX's Hextend and PentaLyte plasma extenders in Japan to treat hypovolemia (low blood volume). Summit will reimburse $900,000 of BTX's development costs. Also, BTX ...